Novo Nordisk Shares Drop Amid Leadership Change and Profit Warnings
TL;DR Summary
Novo Nordisk's stock fell 22% after lowering its 2025 sales and profit growth forecasts and appointing Maziar Mike Doustdar as the new CEO, amid increased competition for its diabetes and obesity drugs.
- Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. Investor's Business Daily
- Novo Nordisk shares plunge 23% after Wegovy maker names new CEO, cuts full-year guidance CNBC
- Novo Nordisk Shares Plummet as Competition Weighs on Sales The Wall Street Journal
- Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook Yahoo Finance
- Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning The New York Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
87%
255 → 32 words
Want the full story? Read the original article
Read on Investor's Business Daily